Drug
Argx 110
Argx 110: highest development phase Phase 1/2, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-110 NCT03030612 | Phase 1/2 | Leukemia, Myeloid, Acute |
Latest
No recent events.
Follow Argx 110 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.